Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'App-A-Thon' Aims To Create PrecisionFDA Software Library To Advance Next-Gen Sequencing

Executive Summary

US FDA is challenging stakeholders to develop apps that users of its precisionFDA platform can leverage to advance next-generation sequencing technology. Results from the competition will be announced by Commissioner Robert Califf next month in Washington, DC.

You may also be interested in...

Q&A: FDA Dx Reviewer's Tips For Next-Gen Sequencing Sponsors

A top reviewer in US FDA's in vitro diagnostics office offers tips to next-generation sequencing test sponsors to avoid common submission shortcomings in this interview with Medtech Insight. According to FDA's Hisani Madison, sponsors frequently fall short in providing a refined intended-use statement.

White House Unveils Actions To Speed Precision Medicine

The White House on Feb. 25 unveiled new actions and commitments from government agencies, including the National Institutes of Health (NIH) and the FDA, and private-sector participants, including Pfizer Inc. and Roche AG unit Genentech Inc., aimed at speeding President Barack Obama's Precision Medicine Initiative (PMI) forward.

A Sharing Tool For Next-Gen Sequencing: FDA Launches precisionFDA

As scheduled, FDA has launched its precisonFDA portal that the agency says will aggregate research data to help develop and verify next generation sequencing diagnostic tests.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts